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How Low Is Low Enough?*Alan H. Gradman, MDT he study by Bangalore et al. (1) that appearsin this issue of the Journal addresses themost pressing topic in antihypertensive ther-
apy today: determining the optimal thresholds and
targets for treatment in various segments of the hy-
pertensive population. The paper is a direct responseSEE PAGE 784to the recent publication of the 2014 Evidence-Based
Guidelines for the Management of High Blood Pressure
in Adults, authored by panel members of the Eighth
Joint National Committee on Prevention, Detection,
Evaluation, and Treatment of High Blood Pressure
(JNC-8), originally appointed by the National Heart,
Lung, and Blood Institute, and dedicated to the hy-
pothesis that appropriate guidelines should be based
exclusively on data derived from randomized clinical
trials (RCTs) (2). After analyzing available RCT data,
the JNC 8 panel concluded that the blood pressure
(BP) threshold and target for treatment in patients
>60 years of age without diabetes or chronic kidney
disease should be 150/90 mm Hg rather than 140/90
mm Hg, as recommended in the Seventh Report of
the Joint National Committee on Prevention, Detec-
tion, Evaluation, and Treatment of High Blood Pres-
sure (JNC-7). They considered this recommendation
to be strongly evidence-based. It was acknowledged,
however, that only “low-quality” evidence supported
the conclusion that there was no additional beneﬁt
to be gained from “setting a goal [systolic] BP lower
than 140 mm Hg in this age group.” The panel’s*Editorials published in the Journal of the American College of Cardiology
reﬂect the views of the authors and do not necessarily represent the
views of JACC or the American College of Cardiology.
From the Temple University School of Medicine (Clinical Campus),
Pittsburgh, Pennsylvania. Dr. Gradman has reported that he has no
relationships relevant to the contents of this paper to disclose.recommendation for less aggressive treatment in
older adults has proved to be the most contentious
aspect of the recommendations, even among the
panel members themselves, some of whom strongly
criticized their own paper in a subsequent publication
(3).
Treatment of hypertension in the elderly consti-
tutes one of the great success stories in cardiovas-
cular medicine, and it is important not to endanger
the gains that have been achieved. Clinical trials in
elderly patients with isolated systolic hypertension,
as well as those with systolic/diastolic BP elevation,
have documented relative risk reductions for stroke,
myocardial infarction (MI), and heart failure equal to
or greater than those seen in younger individuals (4).
In HYVET (Hypertension in the Very Elderly Trial),
drug treatment reduced overall mortality by 28%,
stroke by 34%, and new-onset heart failure by a
remarkable 72% in patients >80 years of age (5).
Because age is the most potent determinant of
cardiovascular risk, the same magnitude of risk
reduction translates into the prevention of many
more clinical events per 1,000 patients treated in
elderly compared with younger people with hyper-
tension. If the JNC-8 panel recommendations are
implemented, approximately 6 million fewer adults
in the United States would be deemed eligible for
drug therapy, and treatment intensity would be
reduced for an additional 13.5 million individuals (6).
The paper by Bangalore et al. (1) supports a lower
BP target, speciﬁcally in patients with hypertension
and coronary artery disease (CAD). Their data are
derived from retrospective analysis of the INVEST
(INternational VErapamil SR Trandolapril STudy),
which randomized hypertensive patients with CAD
to receive atenolol or verapamil-SR (sustained
release) as their primary antihypertensive agent.
Patients >60 years of age from either treatment group
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795who entered the trial with a baseline systolic blood
pressure (SBP) >150 mm Hg were analyzed. Those
with an on-treatment BP <140 mm Hg were found
to have a lower risk of the combined endpoint of
all-cause death, nonfatal MI, and nonfatal stroke than
those with on-treatment SBP of 140 to 149 mm Hg
or >150 mm Hg. After adjustment for baseline patient
variables, cardiovascular mortality and stroke re-
mained signiﬁcantly less frequent in patients with
on-treatment SBP <140 mm Hg than in those with
SBP of 140 to 149 mm Hg. The implication is that the
appropriate target BP in this patient population
should be <140 mm Hg rather than <150 mm Hg, as
recommended by the JNC-8 panel.
It is important to recognize that these results
cannot be used as evidence against the JNC 8 panel’s
selection of 150 mm Hg as the threshold for treat-
ment. All patients in the analyzed cohort entered
INVEST with an SBP of >150 mm Hg, and all would
have been treated according to the new panel guide-
lines. Although thresholds for treatment and treat-
ment targets are often thought of as identical, they
are not. In HYVET, patients were eligible for inclusion
only if they exhibited a sustained SBP >160 mm Hg,
and once randomized, the BP target was 150/80
mm Hg. Determining the proper threshold for treat-
ment in the elderly is particularly challenging,
because not only HYVET but all the major clinical
trials in elderly hypertensive people have random-
ized patients with a baseline SBP of >160 mm Hg.
Thus, there is little, if any, RCT evidence that treat-
ment of older adults with SBP between 140 and 160
mm Hg actually reduces cardiovascular events (7).
This information was critical to the JNC-8 panel’s
decision to raise the treatment threshold for elderly
patients, although many have questioned application
of this less stringent guideline at the relatively young
age of 60 years. From a public health perspective,
there is a compelling need for a well-designed, pla-
cebo-controlled trial to determine the optimal
threshold for treatment in this large segment of the
adult population.
With regard to selection of the optimal BP targets,
the study results are of considerable interest, but
they are subject to interpretation. Physicians in
INVEST were given speciﬁc BP goals: <140/90 mm Hg
for “uncomplicated” patients and <130/85 mm Hg
for those with diabetes and/or renal impairment.
Although 57% of patients achieved <140 mm Hg, 43%
did not, despite having received the same initial
treatments and having had physicians who were given
identical instructions regarding BP management.
In effect, the authors have compared the progno-
sis of “responders” to “nonresponders,” using thepost-randomization variable of achieved on-treatment
BP as a measure of response. There is considerable
evidence that response to treatment is itself a function
of patient characteristics, known or unknown, that
may independently inﬂuence prognosis (8). In this
study, patients who did not achieve an on-treatment
BP <140 mm Hg were older, had a higher baseline
SBP, and had a higher prevalence of major comorbid-
ities, including diabetes and renal insufﬁciency,
characteristics known both to adversely affect prog-
nosis and to reduce the response to antihypertensive
drug therapy. Although the authors endeavored to
statistically correct for many known variables, their
data lack the effect of randomization, which serves
to equalize all baseline characteristics of a studied
population.
In the present study, JNC-7 BP targets were set by
protocol, and a predictable heterogeneity of response
to treatment was observed. The lower risk exhibited
by that portion of the study population that achieved
an on-treatment BP <140 mm Hg suggests that
treatment should be given to all patients to lower BP
into that range. However, the efﬁcacy of using the
JNC-7 targets, as was done in this study, must include
the sum of all cardiovascular events and adverse ex-
periences that occurred in patients who did and did
not achieve those targets. In published analyses of
achieved BP data, the authors attempted to identify
the optimal on-treatment BP, the “sweet spot” at
which cardiovascular risk is minimized. Although
such analyses may accurately identify an “ideal”
BP, this BP cannot be consistently attained in a real-
world population of hypertensive patients. There
will always be a spectrum of response, with some
patients falling above and some below the ideal BP.
To adjudicate between a target of 140 mm Hg and
150 mm Hg, it would be necessary to perform a pro-
spective trial in which the population was random-
ized to these targets and the overall results were
compared.
In the absence of such data, and given the depth
and duration of this controversy, it is clear that there
is no right answer. As was seen in ACCORD (Action
to Control Cardiovascular Risk in Diabetes), more
aggressive treatment of nonresponders could be
accompanied by an increased number of treatment-
related adverse events in this relatively “resistant”
segment of the older hypertensive population. In
patients with CAD, concern about the J curve and the
possibility of an increased risk of coronary events has
tempered enthusiasm for aggressive BP reduction,
particularly in older patients with low diastolic BP.
In the TNT (Treating to New Targets) study, in
which 10,001 patients with CAD were analyzed, an
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796on-treatment BP of 146/81 mm Hg was identiﬁed as
being associated with the lowest risk of a combined
endpoint that included MI and stroke (9). However,
unlike INVEST, the study was not conducted specif-
ically in hypertensive patients.
My overall sense is that the JNC-8 panel recom-
mendations are reasonable for patients with hyper-
tension and CAD. Retention of the diastolic BP
target of <90 mm Hg ensures that patients with sig-
niﬁcant systolic/diastolic hypertension will be treated
regardless of their SBP. For high-risk diabetic
patients, the lower target of <140/90 mm Hg is
recommended for all patients, regardless of age. For
patients with isolated systolic hypertension and an
SBP in the 140s, clinical judgment will be required.
Patients at increased risk of stroke should probably
receive more intensive treatment, because thisendpoint, unlike MI, is particularly sensitive to BP
reduction. Practitioners should carefully note the
corollary recommendation given by the JNC-8 panel
that “if pharmacologic treatment for high BP results
in lower achieved SBP (e.g., <140 mm Hg) and treat-
ment is not associated with adverse effects on health
or quality of life, treatment does not need to be
adjusted.” It is worth noting that this corollary
recommendation was based not on the results of
RCTs but on that imprecise, oft-criticized “expert
opinion.” Fortunately, or unfortunately, this will
remain an essential component in the clinical care of
patients with hypertension and CAD.
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